Want to see GB:AMS full AI Analyst Report?
Top Page
Advanced Medical Solutions
(LSE:AMS)
Select Model
Select Model
Rating:63Neutral
Price Target:
299.00 p
▲(6.22% Upside)
Action:Reiterated
Date:08/07/26
The score is anchored by mixed financial performance: improving revenue and cash generation, but materially weaker margins/returns and higher leverage than prior years. Technicals are a clear positive with the stock in a strong uptrend, but the high P/E and modest dividend yield weigh on the overall rating.
Positive Factors
Recurring medical consumables model
AMS sells consumable products used repeatedly in routine wound care and surgical procedures, creating a recurring revenue foundation rather than relying mainly on infrequent equipment purchases. This supports ongoing customer demand and provides a durable platform for serving hospital and community-care channels.
Negative Factors
Material margin compression
The sharp decline in net and EBIT margins shows that revenue growth is translating into substantially less profit than in 2021–2022. Persistently weaker profitability could limit reinvestment, reduce the benefit of scale, and leave earnings more exposed to cost pressure or unfavorable product mix.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring medical consumables model
AMS sells consumable products used repeatedly in routine wound care and surgical procedures, creating a recurring revenue foundation rather than relying mainly on infrequent equipment purchases. This supports ongoing customer demand and provides a durable platform for serving hospital and community-care channels.
Read all positive factors
Advanced Medical Solutions (AMS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£610.26M
Dividend Yield1.67%
Average Volume (3M)1.92M
Price to Earnings (P/E)165.6
Beta (1Y)1.03
Revenue Growth6.05%
EPS Growth-60.00%
CountryUK
Employees1,800
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.02
Shares Outstanding219,604,170
10 Day Avg. Volume1,075,780
30 Day Avg. Volume1,915,421
Financial Highlights & Ratios
PEG Ratio1.19
Price to Book (P/B)1.82
Price to Sales (P/S)2.05
P/FCF Ratio21.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)£245.70M
Advanced Medical Solutions Business Overview & Revenue Model
Company Description
Advanced Medical Solutions Group plc (AMS), along with its subsidiaries, specializes in the innovation, production, and worldwide distribution of advanced medical solutions. Its primary markets include wound treatment, surgical procedures, and wou...
How the Company Makes Money
AMS makes money primarily by selling medical devices and consumable products used in surgery and wound management. Key revenue streams include: (1) Branded product sales: revenue from AMS-owned products (e.g., tissue adhesives, internal sealants, ...
Advanced Medical Solutions Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 233.63M | 228.94M | 177.52M | 126.21M | 124.33M | 108.60M |
| Gross Profit | 112.01M | 108.78M | 82.77M | 70.14M | 68.62M | 56.12M |
| EBITDA | 48.30M | 43.39M | 29.68M | 31.40M | 34.94M | 31.55M |
| Net Income | 3.68M | 9.95M | 7.09M | 15.89M | 20.41M | 17.48M |
Balance Sheet | ||||||
| Total Assets | 392.16M | 394.77M | 389.00M | 289.17M | 281.09M | 249.51M |
| Cash, Cash Equivalents and Short-Term Investments | 13.56M | 18.02M | 17.04M | 60.16M | 82.26M | 72.97M |
| Total Debt | 85.37M | 81.52M | 89.65M | 9.14M | 9.75M | 9.86M |
| Total Liabilities | 136.86M | 134.67M | 147.48M | 44.97M | 44.47M | 36.83M |
| Stockholders Equity | 254.10M | 258.79M | 240.78M | 244.20M | 236.62M | 212.68M |
Cash Flow | ||||||
| Free Cash Flow | 7.95M | 21.39M | 12.67M | 2.50M | 17.12M | 23.95M |
| Operating Cash Flow | 20.38M | 28.75M | 16.73M | 12.35M | 27.08M | 30.41M |
| Investing Cash Flow | -17.79M | -13.54M | -67.15M | -20.27M | -12.70M | -6.41M |
| Financing Cash Flow | -8.28M | -14.92M | 5.48M | -13.62M | -5.70M | -4.41M |
Advanced Medical Solutions Technical Analysis
Positive
281.50
Price Trends
281.28
Positive
264.41
Positive
240.41
Positive
Market Momentum
0.43
Positive
50.76
Neutral
38.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AMS, the sentiment is Positive. The current price of 281.5 is below the 20-day moving average (MA) of 281.68, above the 50-day MA of 281.28, and above the 200-day MA of 240.41, indicating a neutral trend. The MACD of 0.43 indicates Positive momentum. The RSI at 50.76 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AMS.
Advanced Medical Solutions Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £199.51M | 25.79 | 23.64% | 3.34% | 13.71% | 27.65% | |
70 Outperform | £4.18B | 45.69 | 8.40% | 2.56% | 1.94% | -43.71% | |
68 Neutral | £283.66M | 40.36 | 10.01% | 2.30% | 3.26% | 32.54% | |
64 Neutral | £993.86M | -525.53 | -0.26% | 0.61% | 1.97% | -110.22% | |
63 Neutral | £610.26M | 165.59 | 1.44% | 1.67% | 6.05% | -60.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £263.81M | ― | ― | ― | -4.11% | -96.92% |
* Healthcare Sector Average
GB:AMS
Advanced Medical Solutions
281.50
56.58
25.16%
GB:NIOX
Circassia Pharmaceuticals
67.40
-4.74
-6.57%
GB:CTEC
ConvaTec
218.40
-16.00
-6.83%
GB:PRTC
PureTech Health
109.00
-25.80
-19.14%
GB:SPI
Spire Healthcare
247.00
8.13
3.40%
GB:TSTL
Tristel
425.00
76.27
21.87%
Advanced Medical Solutions Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance
AMS grows revenue and margins as H.B. Fuller takeover advances
Positive
Sep 16, 2026
Advanced Medical Solutions reported a 4% rise in group revenue to £115.5 million for the first half of 2026, driven by solid growth in its Surgical and Advanced Woundcare units despite a tougher comparator for U.S. LiquiBand sales. Improved g...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
AMS and H.B. Fuller Set Clean Team Framework for Planned Acquisition
Positive
Sep 1, 2026
Advanced Medical Solutions Group and H.B. Fuller have signed a clean team agreement ahead of H.B. Fuller’s recommended cash acquisition of the UK-based medical technology company via a court-sanctioned scheme of arrangement. The agreement go...
Business Operations and StrategyM&A TransactionsShareholder Meetings
AMS Shareholders Back H.B. Fuller Cash Takeover Scheme
Positive
Aug 12, 2026
Shareholders of Advanced Medical Solutions Group plc have approved all resolutions required to proceed with the recommended cash acquisition by H.B. Fuller Medical Adhesive Technologies Inc. A court-sanctioned scheme of arrangement will be used to...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsShareholder Meetings
AMS publishes scheme document for H.B. Fuller cash takeover and AIM delisting
Positive
Jul 20, 2026
Advanced Medical Solutions Group PLC has published its formal scheme document for the recommended cash acquisition by H.B. Fuller Medical Adhesive Technologies, a wholly owned subsidiary of U.S.-listed H.B. Fuller Company. The deal, structured via...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
AMS posts higher H1 revenues and stays on track for full-year EBITDA
Positive
Jul 20, 2026
Advanced Medical Solutions expects to report half-year 2026 revenues of about £115.2 million, up from £110.8 million a year earlier, despite some orders slipping into July and de-stocking linked to its push to expand direct sales in Euro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.